13.14USD-2.34%Mkt Cap: 489.01M USDP/E: —Last update: 2026-06-01
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap489.01M USD
Enterprise Value264.97M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-59.98M USD
Revenue/Share—
Last Price13.14 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees51
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.44
PEG—
EV/EBITDA-3.98
EV/Revenue—
P/S—
P/B2.02
EPS (TTM)-1.94
EPS (Forward)-1.81
52W Range
3.42575% of range16.33
52W High16.33 USD
52W Low3.425 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.98%
ROA-21.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-55.31M USD
CapEx (TTM)231.00K USD
FCF Margin—
FCF Yield-7.98%
Net Debt-239.37M USD
Net Debt/EBITDA3.60
Balance Sheet
Debt/Equity0.03
Current Ratio38.00
Quick Ratio37.00
Book Value/Sh6.688 USD
Cash/Share6.589 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)22.33 USD
Target Range16.00 USD – 28.00 USD
# Analysts6
Ownership
Shares Out.32.72M
Float27.59M
Insiders0.98%
Institutions93.98%
Short Interest
Short Ratio5.3d
Short % Float4.36%
Short % Out.3.79%
Shares Short1.42M
Short (prev mo.)3.10M
Technical
SMA 5013.24 (-0.8%)
SMA 20012.27 (+7.0%)
Beta0.89
S&P 52W Chg27.94%
Avg Vol (30d)174.11K
Avg Vol (10d)158.33K
Technical Indicators
RSI (14)49.0
MACD0.0302
MACD Signal0.0861
MACD Hist.-0.0558
BB Upper15.00 USD
BB Middle13.82 USD
BB Lower12.64 USD
BB Width17.09%
ATR (14)0.7640 USD
Vol Ratio (20d)0.35x